Drug & intervention

levodopa

RxCUI 6375

Clinical trials21
Recruiting1
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

L-DOPA

l-DOPA, also known as l-3,4-dihydroxyphenylalanine and used medically as levodopa, is made and used as part of the normal biology of some plants and animals, including humans. Humans, as well as a portion of the other animals that utilize l-DOPA, make it via biosynthesis from the amino acid l-tyrosine. l-DOPA is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), which are collectively known as catecholamines. Furthermore, l-DOPA itself mediates neurotrophic factor release by the brain and central nervous system. In some plant families (of the order Caryophyllales), l-DOPA is the central precursor of a biosynthetic pathway that produces a class of pigments called betalains. l-DOPA can be manufactured and in its pure form is sold as a drug with the INNTooltip International Nonproprietary Name levodopa. As a drug, it is used in the treatment of Parkinson's disease and dopamine-responsive dystonia, as well as restless leg syndrome. l-DOPA has a counterpart with opposite chirality, d-DOPA. As is true for many molecules, the human body produces only one of these isomers (the l-DOPA form). The enantiomeric purity of l-DOPA may be analyzed by determination of the optical rotation or by chiral thin-layer chromatography.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

21 shown
Cortical Electrophysiology of Response Inhibition in Parkinson's DiseaseNCT06234995 · 2021-08-09
RECRUITING
Levodopa for Diabetic RetinopathyNCT07444892 · 2022-04-18
COMPLETED
The Correlation of Reduction of Levodopa and Non-motor Symptoms of Parkinson's Disease After Deep Brain StimulationNCT05901350 · 2019-06-01
COMPLETED
Behavioural Profiling of Disease-related Cognitive and Motor Impairment in PDNCT06275633 · 2019-03-19
COMPLETED
Measuring Parkinson's Disease ProgressionNCT03205956 · 2017-10-19
COMPLETED
Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's DiseaseNCT03119636 · 2017-05-01
UNKNOWN
A Study to Evaluate SAGE-217 in Participants With Parkinson's DiseaseNCT03000569 · 2016-11-30
COMPLETED
Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's DiseaseNCT02601586 · 2016-09-01
COMPLETED
A Study of L-DOPA for Depression and Slowing in Older AdultsNCT02744391 · 2016-08-24
COMPLETED
Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's DiseaseNCT02641054 · 2016-02-01
COMPLETED
Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ONNCT02769793 · 2015-06-01
COMPLETED
Cardiovascular Events in Parkinson's Disease PatientsNCT01545856 · 2011-09-01
COMPLETED
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.NCT01227655 · 2011-03-01
COMPLETED
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonNCT01568073 · 2011-03-01
COMPLETED
Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)NCT00845000 · 2009-04-21
COMPLETED
Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive ImpairmentNCT00306124 · 2006-01-01
UNKNOWN
Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's DiseaseNCT00153972 · 2005-02-01
COMPLETED
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's DiseaseNCT00096720 · 2004-02-01
COMPLETED
Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) StudyNCT01044992 · 2002-05-01
COMPLETED
Timing of Levodopa Treatment in Parkinson's DiseaseNCT00004733 · 1998-01-01
COMPLETED
Use of Zolpidem in Parkinson's DiseaseNCT01351168
WITHDRAWN

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.